Three dimensions of the amyloid hypothesis: time, space and 'wingmen'
暂无分享,去创建一个
[1] Florence Pasquier,et al. Phenotype associated with APP duplication in five families. , 2006, Brain : a journal of neurology.
[2] D. Selkoe,et al. Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration , 2011, Proceedings of the National Academy of Sciences.
[3] Maiken Nedergaard,et al. Impairment of paravascular clearance pathways in the aging brain , 2014, Annals of neurology.
[4] D. Holtzman,et al. Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis , 2011, The Journal of Neuroscience.
[5] H. Braak,et al. The pathological process underlying Alzheimer’s disease in individuals under thirty , 2011, Acta Neuropathologica.
[6] D. Borchelt,et al. Reversible Pathologic and Cognitive Phenotypes in an Inducible Model of Alzheimer-Amyloidosis , 2013, The Journal of Neuroscience.
[7] Nick C Fox,et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.
[8] S. Paul,et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. , 1997, Nature genetics.
[9] A. Fagan,et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study , 2013, The Lancet Neurology.
[10] J. Troncoso,et al. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease , 1994, The Lancet.
[11] T. Prolla,et al. Increased mtDNA mutations with aging promotes amyloid accumulation and brain atrophy in the APP/Ld transgenic mouse model of Alzheimer’s disease , 2014, Molecular Neurodegeneration.
[12] Holly Soares,et al. Cerebrospinal fluid β-amyloid1–42 and tau in control subjects at risk for Alzheimer’s disease: The effect of APOE ε4 allele , 2004, Biological Psychiatry.
[13] D. Holtzman,et al. Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2 , 2014, Molecular Neurodegeneration.
[14] C. Cotman,et al. Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome. , 2001, Neurobiology of disease.
[15] G. Waldemar,et al. Alzheimer disease‐like clinical phenotype in a family with FTDP‐17 caused by a MAPT R406W mutation , 2008, European journal of neurology.
[16] Menno P. Witter,et al. Trans-Synaptic Spread of Tau Pathology In Vivo , 2012, PloS one.
[17] C. Jack,et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.
[18] R. Nitsch,et al. Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.
[19] D. Campion,et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy , 2006, Nature Genetics.
[20] M N Rossor,et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. , 2013, Revue neurologique.
[21] I. Lieberburg,et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. , 1990, Science.
[22] M. Arimon,et al. Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer’s disease , 2013, Acta Neuropathologica.
[23] C. Holmes,et al. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer’s disease , 2010, Acta Neuropathologica.
[24] Nick C Fox,et al. Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders , 2009, Current Alzheimer research.
[25] Basavaraj Hooli,et al. A three-dimensional human neural cell culture model of Alzheimer’s disease , 2014, Nature.
[26] Hui Zheng,et al. Biology and pathophysiology of the amyloid precursor protein , 2011, Molecular Neurodegeneration.
[27] L. Grinberg,et al. Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies , 2014, Neuron.
[28] J. Morris,et al. Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease , 1996, The Journal of Neuroscience.
[29] M. Hipp,et al. Proteostasis impairment in protein-misfolding and -aggregation diseases. , 2014, Trends in cell biology.
[30] Xin Wu,et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.
[31] B. de Strooper. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. , 2010, Physiological reviews.
[32] A. Shah,et al. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions , 2013, Proceedings of the National Academy of Sciences.
[33] B. Strooper. Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process , 2010 .
[34] A. Fagan,et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later , 2013, Alzheimer's & Dementia.
[35] C. Soto,et al. Smoking exacerbates amyloid pathology in a mouse model of Alzheimer’s disease , 2013, Nature Communications.
[36] B. Hyman,et al. Gene Transfer of Human Apoe Isoforms Results in Differential Modulation of Amyloid Deposition and Neurotoxicity in Mouse Brain , 2013, Science Translational Medicine.
[37] M. Farrer,et al. Molecular mapping of alzheimer‐type dementia in Down's syndrome , 1998, Annals of neurology.
[38] C R Jack,et al. Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects , 2010, Neurology.
[39] A. Pestronk,et al. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. , 2014, JAMA neurology.
[40] J. Growdon,et al. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. , 2010, Brain : a journal of neurology.
[41] E. Mandelkow,et al. Aβ Oligomers Cause Localized Ca2+ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines , 2010, The Journal of Neuroscience.
[42] D. Selkoe,et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. , 1992, Nature.
[43] H. Soininen,et al. Hyperphosphorylated tau in young and middle-aged subjects , 2011, Acta Neuropathologica.
[44] A. Fagan,et al. Visinin‐like protein‐1: Diagnostic and prognostic biomarker in Alzheimer disease , 2011, Annals of neurology.
[45] Rie Teraoka,et al. A Mouse Model of Amyloid β Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss In Vivo , 2010, The Journal of Neuroscience.
[46] D. Walsh,et al. Exogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host , 2006, Science.
[47] Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later , 2013, Neurology.
[48] L. Mucke,et al. Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. , 2012, Cold Spring Harbor perspectives in medicine.
[49] J. Price,et al. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease , 1991, Neurobiology of Aging.
[50] L. Mucke,et al. Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.
[51] D. Selkoe,et al. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production , 1992, Nature.
[52] M. Vitek,et al. Tau is essential to β-amyloid-induced neurotoxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[53] K. Kosik,et al. Selective Phosphorylation of Adult Tau Isoforms in Mature Hippocampal Neurons Exposed to Fibrillar Aβ , 1997, Molecular and Cellular Neuroscience.
[54] Bradley T. Hyman,et al. Distribution of Alzheimer‐type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease , 1992, Neurology.
[55] A. Fagan,et al. Human and Murine ApoE Markedly Alters Aβ Metabolism before and after Plaque Formation in a Mouse Model of Alzheimer's Disease , 2002, Neurobiology of Disease.
[56] B. Hyman,et al. Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.
[57] Makoto Hashimoto,et al. β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[58] D. Holtzman,et al. Amyloid‐beta oligomerization in Alzheimer dementia versus high‐pathology controls , 2013, Annals of neurology.
[59] W. Benzing,et al. Evidence for glial-mediated inflammation in aged APPSW transgenic mice , 1999, Neurobiology of Aging.
[60] M. L. Schmidt,et al. Autosomal dominant dementia with widespread neurofibrillary tangles , 1997, Annals of neurology.
[61] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[62] A. Gillespie,et al. Reducing Human Apolipoprotein E Levels Attenuates Age-Dependent Aβ Accumulation in Mutant Human Amyloid Precursor Protein Transgenic Mice , 2012, The Journal of Neuroscience.
[63] Seth Love,et al. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.
[64] L. Mucke,et al. Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease , 2011, The Journal of Neuroscience.
[65] Michela Gallagher,et al. A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.
[66] E. Mandelkow,et al. Fyn-Tau-Amyloid: A Toxic Triad , 2010, Cell.
[67] L. Wilkins. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease , 2017, Neurology.
[68] J. Hardy,et al. Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.
[69] M. Pericak-Vance,et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.
[70] A. Korczyn. The amyloid cascade hypothesis , 2008, Alzheimer's & Dementia.
[71] C. Cotman,et al. Oxidation of Aβ and Plaque Biogenesis in Alzheimer's Disease and Down Syndrome , 2001, Neurobiology of Disease.
[72] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[73] Nick C Fox,et al. Symptom onset in autosomal dominant Alzheimer disease , 2014, Neurology.
[74] L A Hansen,et al. The importance of neuritic plaques and tangles to the development and evolution of AD , 2004, Neurology.
[75] Holly Soares,et al. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. , 2004, Biological psychiatry.
[76] Y. Xiong,et al. Pittsburgh compound B retention and progression of cognitive status – a meta‐analysis , 2014, European journal of neurology.
[77] Jee Hoon Roh,et al. Neuronal activity regulates the regional vulnerability to amyloid-β deposition , 2011, Nature Neuroscience.
[78] B. de Strooper,et al. Modification of γ-secretase by nitrosative stress links neuronal ageing to sporadic Alzheimer's disease , 2012, EMBO molecular medicine.
[79] Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. , 1990, Science.
[80] William T. Hu,et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease , 2014, Nature Medicine.
[81] David A. Bennett,et al. REST and Stress Resistance in Aging and Alzheimer’s Disease , 2014, Nature.
[82] P. Reddy,et al. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. , 2011, Human molecular genetics.
[83] D. Bennett,et al. Soluble α-Synuclein Is a Novel Modulator of Alzheimer's Disease Pathophysiology , 2012, The Journal of Neuroscience.
[84] Cornelia M. Wilson,et al. Tau protein kinases: Involvement in Alzheimer's disease , 2013, Ageing Research Reviews.
[85] T. Saido,et al. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Aβ to physiologically relevant proteolytic degradation , 2003, The Lancet.
[86] G. Rebeck,et al. Aging reduces glial uptake and promotes extracellular accumulation of Aβ from a lentiviral vector , 2014, Front. Aging Neurosci..
[87] Seiji Nishino,et al. Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle , 2009, Science.
[88] D. Holtzman,et al. Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis , 2012, The Journal of experimental medicine.
[89] V. Preedy,et al. Prospective Cohort Study , 2010 .
[90] C. Masters,et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.
[91] C. Jack,et al. TDP-43 is a key player in the clinical features associated with Alzheimer’s disease , 2014, Acta Neuropathologica.
[92] Bin Zhang,et al. Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons , 2013, Cell.
[93] A. Pestronk,et al. TREM 2 Variant p . R 47 H as a Risk Factor for Sporadic Amyotrophic Lateral Sclerosis , 2014 .
[94] Kewei Chen,et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. , 2011, Journal of Alzheimer's disease : JAD.
[95] R. Petersen,et al. neurodegeneration : evidence for association of the p . R 47 H variant with frontotemporal dementia and Parkinson ¿ s disease Permalink , 2013 .
[96] Keith A. Johnson,et al. Neuropathology of Cognitively Normal Elderly , 2003, Journal of neuropathology and experimental neurology.
[97] K. Zahs,et al. Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults. , 2013, JAMA neurology.
[98] D. Borchelt,et al. Normal cognition in transgenic BRI2-Aβ mice , 2013, Molecular Neurodegeneration.
[99] J. Hardy,et al. Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.
[100] C. Geula,et al. A Lifespan Observation of a Novel Mouse Model: In Vivo Evidence Supports Aβ Oligomer Hypothesis , 2014, PloS one.
[101] R. Sperling,et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. , 2014, JAMA neurology.
[102] Daniel J. R. Christensen,et al. Sleep Drives Metabolite Clearance from the Adult Brain , 2013, Science.
[103] J. Morris,et al. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.
[104] G. Halliday,et al. Variations in the neuropathology of familial Alzheimer’s disease , 2009, Acta Neuropathologica.
[105] J. Kelly,et al. The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. , 2007, Biochemistry.
[106] E. Masliah,et al. Alpha‐synuclein in Lewy Body Disease and Alzheimer's Disease , 1999, Brain pathology.
[107] Ralph A. Nixon,et al. Autophagy failure in Alzheimer's disease—locating the primary defect , 2011, Neurobiology of Disease.
[108] Richard Hollister,et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease , 1997, Annals of neurology.
[109] J. Keller,et al. Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis. , 2013, Free radical biology & medicine.
[110] Naruhiko Sahara,et al. Propagation of Tau Pathology in a Model of Early Alzheimer's Disease , 2012, Neuron.
[111] John Q Trojanowski,et al. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. , 2010, The American journal of pathology.
[112] L. Mucke,et al. Amyloid-beta / Fyn – Induced Synaptic , Network , and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer ’ s Disease , 2015 .
[113] Bradley T. Hyman,et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.
[114] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[115] M. Vitek,et al. Tau is essential to beta -amyloid-induced neurotoxicity. , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[116] C. Rowe,et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.
[117] Jürgen Götz,et al. Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.
[118] K. Sleegers,et al. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. , 2006, Brain : a journal of neurology.
[119] B. de Strooper,et al. The mechanism of γ-Secretase dysfunction in familial Alzheimer disease , 2012, The EMBO journal.
[120] E. Tangalos,et al. Neuropathologic features of amnestic mild cognitive impairment. , 2006, Archives of neurology.
[121] Yasuyoshi Watanabe,et al. A new amyloid β variant favoring oligomerization in Alzheimer's‐type dementia , 2008, Annals of neurology.
[122] A. Dillin,et al. Aging as an event of proteostasis collapse. , 2011, Cold Spring Harbor perspectives in biology.
[123] D. Holtzman,et al. Apolipoprotein E in Alzheimer's disease and other neurological disorders , 2011, The Lancet Neurology.
[124] A. Fagan,et al. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition , 2008, Proceedings of the National Academy of Sciences.
[125] J Q Trojanowski,et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. , 1998, The American journal of pathology.
[126] L. Mucke,et al. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[127] David A Bennett,et al. Brain amyloid-β oligomers in ageing and Alzheimer's disease. , 2013, Brain : a journal of neurology.
[128] H. Vinters,et al. β-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin , 2009, The Journal of Neuroscience.
[129] Christine Van Broeckhoven,et al. Genetic insights in Alzheimer's disease , 2013, The Lancet Neurology.
[130] Virginia M. Y. Lee,et al. Increased Lipid Peroxidation Precedes Amyloid Plaque Formation in an Animal Model of Alzheimer Amyloidosis , 2001, The Journal of Neuroscience.
[131] R. Neve,et al. Impairments in learning and memory accompanied by neurodegeneration in mice transgenic for the carboxyl-terminus of the amyloid precursor protein. , 1999, Brain research. Molecular brain research.
[132] C. Rowe,et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.
[133] Ole A. Andreassen,et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.
[134] C. Glabe,et al. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction , 2009, Neurobiology of Disease.
[135] A. Fagan,et al. APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.
[136] C. Jack,et al. Evidence for ordering of Alzheimer disease biomarkers. , 2011, Archives of neurology.
[137] M. Weiner,et al. Smoking and increased Alzheimer's disease risk: A review of potential mechanisms , 2014, Alzheimer's & Dementia.
[138] J. Hardy,et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). , 1997, Human molecular genetics.
[139] J. Gunter,et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease , 2012, Neurology.
[140] S. Pimplikar,et al. The γ-secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[141] C. Rowe,et al. Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition , 2012, Neurology.
[142] M. Pasparakis,et al. IKKβ Deficiency in Myeloid Cells Ameliorates Alzheimer's Disease-Related Symptoms and Pathology , 2014, The Journal of Neuroscience.
[143] J. Trojanowski,et al. Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein , 2003, Science.
[144] David M Holtzman,et al. Human Apoe Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance Nih Public Access , 2022 .
[145] M. Gallagher,et al. A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.
[146] J. Morris,et al. Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.
[147] Michael Weiner,et al. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease , 2009, Annals of neurology.